Omalizumab + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nasal Polyps
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Trial Timeline
May 9, 2018 → Mar 16, 2020
NCT ID
NCT03478930About Omalizumab + Placebo
Omalizumab + Placebo is a phase 3 stage product being developed by Roche for Nasal Polyps. The current trial status is completed. This product is registered under clinical trial identifier NCT03478930. Target conditions include Nasal Polyps, Chronic Rhinosinusitis.
What happened to similar drugs?
8 of 20 similar drugs in Nasal Polyps were approved
Approved (8) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03478930 | Phase 3 | Completed |
| NCT03280537 | Phase 3 | Completed |
| NCT03280550 | Phase 3 | Completed |
Competing Products
20 competing products in Nasal Polyps